{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -1.9607855, "regularMarketPrice": 7.5, "exchange": "FRA", "shortName": "ACTINIUM PHARMAC. DL-,001", "longName": "Actinium Pharmaceuticals, Inc.", "messageBoardId": "finmb_7845787", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683871215, "earningsTimestamp": 1682938740, "earningsTimestampStart": 1682938740, "earningsTimestampEnd": 1682938740, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.2, "epsForward": -0.93, "epsCurrentYear": -1.12, "priceEpsCurrentYear": -6.696429, "sharesOutstanding": 25729400, "bookValue": 2.589, "fiftyDayAverage": 8.4439, "fiftyDayAverageChange": -0.9439001, "fiftyDayAverageChangePercent": -0.11178485, "twoHundredDayAverage": 8.85507, "twoHundredDayAverageChange": -1.3550701, "twoHundredDayAverageChangePercent": -0.1530276, "marketCap": 200084992, "forwardPE": -8.064516, "priceToBook": 2.8968713, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.8 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1416553200000, "priceHint": 2, "regularMarketChange": -0.1500001, "regularMarketDayHigh": 7.5, "regularMarketDayRange": "7.5 - 7.5", "regularMarketDayLow": 7.5, "regularMarketVolume": 500, "regularMarketPreviousClose": 7.65, "bid": 7.6, "ask": 7.7, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 7.5, "averageDailyVolume3Month": 340, "averageDailyVolume10Day": 440, "fiftyTwoWeekLowChange": 3.058, "fiftyTwoWeekLowChangePercent": 0.68842864, "fiftyTwoWeekRange": "4.442 - 19.8", "fiftyTwoWeekHighChange": -12.299999, "fiftyTwoWeekHighChangePercent": -0.6212121, "fiftyTwoWeekLow": 4.442, "fiftyTwoWeekHigh": 19.8, "symbol": "7AY1.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "275 Madison Avenue", "address2": "7th Floor", "city": "New York", "state": "NY", "zip": "10016", "country": "United States", "phone": "646 677 3870", "website": "https://www.actiniumpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sandesh C. Seth M.B.A., M.S., MBA", "age": 58, "title": "Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 1145000, "fmt": "1.15M", "longFmt": "1,145,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1133900, "fmt": "1.13M", "longFmt": "1,133,900"}}, {"maxAge": 1, "name": "Mr. Steven  O'Loughlin BS", "age": 36, "title": "CFO & Corp. Sec.", "yearBorn": 1986, "fiscalYear": 2022, "totalPay": {"raw": 585000, "fmt": "585k", "longFmt": "585,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 370734, "fmt": "370.73k", "longFmt": "370,734"}}, {"maxAge": 1, "name": "Dr. Paul  Diamond Esq., Ph.D.", "title": "VP of Patent & Legal Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David  Gould", "title": "Sr. VP of Corp. Devel. & Corp. Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Bernie  Cunningham P.M.P., Ph.D.", "title": "Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Qing  Liang", "title": "VP & Head of Radiation Sciences", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Robert N. Daly M.S., Ph.D.", "title": "VP & Head of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mamata  Gokhale", "title": "VP & Global Head of Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Avinash  Desai M.D.", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jenny  Hsieh", "title": "Chief Strategy Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}